Lobular breast carcinoma in situ

Summary

Lobular breast carcinoma in situ (MONDO:0006270) is a cancer and 38 clinical trials. Top therapeutic interventions include oxybutynin, metformin, and abemaciclib. A subtype of lobular neoplasia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 38

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lobular breast carcinoma in situ
Mondo ID	MONDO:0006270
EFO	EFO:1000326
ICD-10-CM	D05.0
NCIT	C4018
SNOMED CT	109888004
UMLS	C0279563
MedGen	79007
Is cancer (heuristic)	yes

Also known as: breast lobular carcinoma in situ · LCIS · lobular breast carcinoma in situ · lobular Ca in situ of breast · lobular Ca in situ of the breast · lobular carcinoma in situ · lobular carcinoma in situ (LCIS) · lobular carcinoma in situ of breast · lobular carcinoma in situ of the breast · lobular carcinoma in situ of the breast (LCIS) · non-infiltrating lobular breast carcinoma · non-infiltrating lobular carcinoma · non-infiltrating lobular carcinoma of breast · non-infiltrating lobular carcinoma of the breast · non-invasive lobular breast carcinoma · non-invasive lobular carcinoma of breast · non-invasive lobular carcinoma of the breast

Disease family

This is a subtype of lobular neoplasia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › in situ carcinoma › breast carcinoma in situ › lobular neoplasia › lobular breast carcinoma in situ

Related subtypes (1): atypical lobular breast hyperplasia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 38.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	17
PHASE2	13
PHASE1	6
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01905046	PHASE3	ACTIVE_NOT_RECRUITING	Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
NCT02961790	PHASE3	COMPLETED	Oxybutynin Chloride in Managing Hot Flashes
NCT03936478	PHASE2	RECRUITING	Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
NCT05941520	PHASE2	RECRUITING	Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
NCT06033092	PHASE2	ACTIVE_NOT_RECRUITING	Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion
NCT06184750	PHASE2	RECRUITING	Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
NCT06195306	PHASE2	RECRUITING	Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
NCT01754519	PHASE2	TERMINATED	Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery
NCT01849250	PHASE2	COMPLETED	Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors
NCT01869764	PHASE2	COMPLETED	Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
NCT02137252	PHASE2	TERMINATED	Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
NCT02314156	PHASE2	COMPLETED	Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
NCT02928978	PHASE2	COMPLETED	Ruxolitinib for Premalignant Breast Disease
NCT03979508	PHASE2	TERMINATED	Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
NCT04570956	PHASE2	TERMINATED	Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk
NCT03317405	PHASE1	ACTIVE_NOT_RECRUITING	Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
NCT07408856	PHASE1	NOT_YET_RECRUITING	CAN1012 in Pre-Malignant DCIS and LCIS
NCT00637481	PHASE1	COMPLETED	A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
NCT01077453	PHASE1	COMPLETED	Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer
NCT01372644	PHASE1	COMPLETED	Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial
NCT03323658	PHASE1	COMPLETED	Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
NCT02515110	Not specified	ACTIVE_NOT_RECRUITING	Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer
NCT04496739	Not specified	ACTIVE_NOT_RECRUITING	Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)
NCT05178498	Not specified	RECRUITING	Impact of Dietary Inflammatory Potential on Breast Cancer Risk
NCT00620087	Not specified	COMPLETED	Molecular Breast Imaging in Women With Atypia and LCIS
NCT01219075	Not specified	COMPLETED	Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer
NCT01293032	Not specified	COMPLETED	Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer
NCT01706432	Not specified	COMPLETED	Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
NCT01723943	Not specified	COMPLETED	Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients
NCT01729832	Not specified	WITHDRAWN	Stereotactic Image-Guided Navigation During Breast Reconstruction in Patients With Breast Cancer
NCT01819233	Not specified	COMPLETED	Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy
NCT01874184	Not specified	COMPLETED	Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
NCT01975363	Not specified	COMPLETED	Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer
NCT02216136	Not specified	COMPLETED	Tumor: Breast Ratio Study
NCT03868475	Not specified	WITHDRAWN	Comparing Vacuum-Assisted Percutaneous Excision to Open Surgical Excision for Borderline or High-Risk Breast Lesions
NCT05086705	Not specified	COMPLETED	EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer
NCT05755269	Not specified	TERMINATED	Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women
NCT05868252	Not specified	UNKNOWN	Molecular Analysis of the Sloane Project

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
OXYBUTYNIN	4	3
METFORMIN	4	2
ABEMACICLIB	4	1
ATORVASTATIN	4	1
BEXAROTENE	4	1
OMEGA-3-ACID ETHYL ESTERS	4	1
PASIREOTIDE	4	1
AFIMOXIFENE	3	1
DOCONEXENT	3	1
ENDOXIFEN	3	1
TELAPRISTONE ACETATE	3	1
ACOLBIFENE HYDROCHLORIDE	2	1
SOY ISOFLAVONES	2	1
CHEMBL4439413	0	1
CHEMBL5190225	0	1